Case report: Immune remission from generalized myasthenia gravis in a dog with a thymoma and cholangiocellular carcinoma
Source : https://www.frontiersin.org/articles/10.3389/fvets.2023.1124702/full
A 9-year-old male neutered Cockapoo was presented with an acute and progressive history of exercise induced weakness involving all limbs, and bilateral decreased ability to blink. Investigations revealed generalized myasthenia...
Conclusion: This is the first report describing the temporal evolution of serum AChR antibody concentration in a dog with thymoma-associated myasthenia gravis that achieved immune remission following thymectomy. Treatment was successfully discontinued without any clinical deterioration thereafter despite serum acetylcholine receptor antibody...
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) - Journal of Neurology
Source : https://link.springer.com/article/10.1007/s00415-022-11517-w
There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose disease symptoms are not well controlled. HRQoL measures such as...
Conclusion: Treatment with efgartigimod resulted in significant and rapid HRQoL improvements for up to 8 weeks after the first infusion in TC 1 and TC 2.
Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36979710/
The thymus is widely recognized as an immunological niche where autoimmunity against the acetylcholine receptor (AChR) develops in myasthenia gravis (MG) patients, who mostly present thymic hyperplasia and thymoma. Thymoma-associated...
Conclusions/Relevance: Our findings support the idea that altered muscle autoantigen expression, related with hyperplastic and neoplastic changes, may favor autosensitization in the MG thymus, and that molecular mimicry involving tumor-related muscle-like proteins may be a mechanism that makes thymoma prone to developing MG.
Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-03177-8
Background Nivolumab is an immune checkpoint inhibitor that targets the programmed cell death-1 protein and is effective in treating advanced cancer. However, it is also associated with various immune-related neurological...
Conclusion: Our study indicates the possibility of nivolumab-induced neuropathies in cases involving muscle weakness with sensory abnormalities of the upper extremity following nivolumab administration in patients with advanced cancer. Comprehensive electrodiagnostic studies and magnetic resonance imaging are helpful in the differential...
Thymectomy in thymomatous generalized myasthenia gravis: An analysis of the prognosis and risk factors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36997293/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Male sex and disease duration <11.5 weeks were independent predictors of CSR in TGMG post-thymectomy. Onset age <52.8y and ocular and limb muscle weakness at onset was associated with a higher probability of achieving CSR than onset age >52.8 y and bulbar muscle weakness. Female sex was an independent predictor of MG...